Inhibitory effect of plumbagin,a potential anticancer natural compound,on cytochrome P450 2J2 in humans

被引:0
|
作者
LU Jian [1 ]
LIU Dao-zhi [1 ]
ZHOU Xiao-jing [1 ]
CHEN Ang [1 ]
LIU Ming-yao [1 ,2 ]
WANG Xin [1 ]
机构
[1] Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University
[2] Center for Cancer and Stem Cel Biology,Institute of Biosciences and Technology,Texas A&M University Health Science Center
基金
中国国家自然科学基金;
关键词
plumbagin; astemizole; CYP2J2; antitumor; LC-MS/MS; cytotoxicity;
D O I
暂无
中图分类号
R285 [中药药理学];
学科分类号
1008 ;
摘要
OBJECTIVE Cytochrome P450(CYP)2J2 is highly expressed in many kinds of human tumors and promotes tumor cell growth via regulating the metabolism of arachidonic acids.The purposes of this study were toidentify the new inhibitor of CYP2J2 from natural compounds and evaluate its potential to inhibit hepatoma carcinoma cells.METHODS Total fifty natural products were screened for the inhibitory potency against the activity of CYP2J2-mediated astemizole O-demethylation via LCMS/MS analysis.Enzyme kinetic and molecular docking studies were also carried out.RESULTS Our data found that plumbagin potently inhibited CYP2J2 with IC50value at 3.42,3.37 and 1.17μmol·L-1in rat liver microsomes,human liver microsomes(HLMs)and recombinant CYP2J2(rC YP2J2),respectively.Further enzyme kinetic studies showed that plumbagin was a mixed-type inhibitor of CYP2J2 in HLMs and r CYP2J2 with Kivalues of 1.88and 0.92μmol·L-1,respectively.Docking data presented that plumbagin interacted with CYP2J2 mainly through GLU222 and ALA223,which were crucial residues for substrates binding.At the same time,plumbagin showed cytotoxicity effects on hepatic carcinoma cell lines,such as HepG 2 and SMMC-7721,with IC50values at 11.55±1.06and(13.15±1.11)μmol·L-1,respectively.CONCLUSION These results indicated that plumbagin was a potent CYP2J2 inhibitor and potential anticancer agent.Further studies are needed to cover the mechanism of its antitumor activity.
引用
收藏
页码:1044 / 1044
页数:1
相关论文
共 50 条
  • [21] Unusual regioselectivity and active site topology of human cytochrome p450 2J2
    Lafite, Pierre
    Andre, Francois
    Zeldin, Darryl C.
    Dansette, Patrick M.
    Mansuy, Daniel
    BIOCHEMISTRY, 2007, 46 (36) : 10237 - 10247
  • [22] Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2
    Lafite, Pierre
    Andre, Francois
    Graves, Joan P.
    Zeldin, Darryl C.
    Dansette, Patrick M.
    Mansuy, Daniel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
  • [23] Role of Cytochrome P450 2J2 and Soluble Epoxide Hydrolase in Drug Cardiotoxicity
    Solanki, Meetal Satishkumar
    Jones, Barry
    Dawkins-Hall, Laurence
    Pointon, Amy
    Herbert, Karl
    FASEB JOURNAL, 2018, 32 (01):
  • [24] LKY-047: First Selective Inhibitor of Cytochrome P450 2J2
    Nguyen Minh Phuc
    Wu, Zhexue
    Yuseok, O.
    Lee, Jee-Hyun
    Oh, Sangtaek
    Song, Gyu-Yong
    Liu, Kwang-Hyeon
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (07) : 765 - 769
  • [25] Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine
    Ikemura, Noriaki
    Yamaori, Satoshi
    Kobayashi, Chinatsu
    Kamijo, Shinobu
    Murayama, Norie
    Yamazaki, Hiroshi
    Ohmori, Shigeru
    CHEMICO-BIOLOGICAL INTERACTIONS, 2019, 306 : 1 - 9
  • [26] Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2
    Kojima, Ayaka
    Nadai, Masayuki
    Murayama, Norie
    Yamazaki, Hiroshi
    Katoh, Miki
    XENOBIOTICA, 2022, 52 (07) : 669 - 675
  • [27] Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors
    Ren, Shuang
    Zeng, Juan
    Mei, Ye
    Zhang, John Z. H.
    Yan, S. Frank
    Fei, Jian
    Chen, Li
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (01) : 60 - 71
  • [28] RISK OF HYPERTENSION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH POLYMORPHISM IN CYTOCHROME P450 2J2
    Liao, James K.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 97 : S21 - S21
  • [29] Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
    I El-Serafi
    M Fares
    M Abedi-Valugerdi
    P Afsharian
    A Moshfegh
    Y Terelius
    Z Potácová
    M Hassan
    The Pharmacogenomics Journal, 2015, 15 : 405 - 413
  • [30] Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
    El-Serafi, I.
    Fares, M.
    Abedi-Valugerdi, M.
    Afsharian, P.
    Moshfegh, A.
    Terelius, Y.
    Potacova, Z.
    Hassan, M.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 405 - 413